AI, Gene Editing, Biosimilars, and Real-World Data shaping the future of pharma

The pharmaceutical sector is continuously evolving, with several key patents set to expire in the coming years. To ensure the development of next-generation treatments, companies must stay abreast of the latest trends. Clarivate’s annual Drugs To Watch report highlights new frontiers and significant upcoming developments in the pharmaceutical and biologics markets. This year’s report emphasises themes such as artificial intelligence (AI), gene editing, biosimilars, and real-world data.

AI and machine learning (ML) are revolutionising the drug development pipeline, from lead compound formulation to clinical trial optimisation and pharmacovigilance. AI applications in pharma include identifying promising drug targets, aiding disease diagnosis, repurposing existing drugs, and streamlining clinical trials. The first AI-developed drug candidates are now entering Phase 2 clinical trials, and partnerships like Moderna’s with OpenAI aim to integrate AI across various operations to enhance productivity and safety. Despite the potential, the application of AI in pharma faces regulatory challenges and requires expertise to navigate a rapidly evolving field.

Gene editing has advanced significantly since the CRISPR-Cas9 technology was developed, leading to therapies such as Casgevy for sickle-cell disease and β-thalassemia. This therapy uses CRISPR-Cas9 to switch off faulty adult hemoglobin production and activate fetal hemoglobin. However, the genetic diversity and complexity of diseases pose significant hurdles for gene therapy design, necessitating strategies that account for varied genetic mutations.

Biosimilars, which are near-identical copies of already-licensed biopharmaceuticals, offer a cost-effective alternative to original drugs, potentially increasing patient access. While the adoption of biosimilars like those for Humira has faced economic and regulatory challenges, other drugs like Herceptin have seen significant market share decreases with biosimilar entry. Over time, as familiarity with biosimilars grows, the economic barriers to their adoption are expected to lessen.

Real-world data (RWD) provides insights into drug performance outside clinical settings through sources such as electronic health records and wearable devices. RWD helps inform clinical trial designs, shorten drug development timelines, and support post-market surveillance. Regulatory agencies are increasingly accepting real-world evidence, which can offer more representative data on patient groups often under-represented in clinical trials. AI and ML can enhance the analysis of vast RWD datasets, though challenges related to data quality, access, and patient privacy remain.

These innovations are reshaping the pharmaceutical industry, driving progress, and ensuring the development of future treatments. Key trends to watch in 2024 include the integration of AI in drug development, the expansion of biosimilar use, and the utilisation of real-world data, highlighting the sector’s dynamic nature.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:

More articles like this

Poolbeg Pharma relocates to new London headquarters at 40 Bank Street

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the Company has changed its registered address to 40 Bank Street,

Innovative approaches at Poolbeg Pharma

Poolbeg Pharma plc is dedicated to the development and commercialisation of innovative medicines, particularly those targeting diseases with high unmet medical needs, including rare and orphan diseases. The company’s strategy revolves around developing its promising clinical

GLP-1 receptor agonists transform diabetes treatment

GLP-1 (glucagon-like peptide-1) and its receptor agonists (GLP-1RAs) have emerged as a groundbreaking class of drugs in diabetes management, particularly due to their impressive efficacy in reducing obesity, a key factor in type 2 diabetes. Jeremy

AI revolutionising the pharmaceutical industry

The rapid advancement of artificial intelligence (AI) is making significant strides in the pharmaceutical sector. Since its inception, this industry has embraced AI and machine learning, continuing its legacy of innovation. The integration of these technologies

Poolbeg Pharma publishes Annual Report and AGM Notice

Poolbeg Pharma plc (LON: POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has confirmed that the Company’s Annual Report and Accounts for the period ended

Poolbeg Pharma expands treatment into new markets

Poolbeg Pharma said it had made progress last year in expanding its treatments into new markets, with significant pipeline advancements and strategic deals. The company said it had made a strategic expansion into the treatment of

Poolbeg Pharma granted significant POLB 001 patent in United States

Poolbeg Pharma plc (LON:POLB, OTCQB:POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that, further to its announcement on 20 March 2024, the Company has received the fully granted

AI impact on biopharma business models

The culture of collaboration in the Pacific Northwest, the impact of AI on biopharma, and the shape of new business models driven by AI were all topics at a panel discussion Wednesday in Seattle at the